Proteomic Biomarkers in VTE: From Discovery to Clinical Translation
Journal of Clinical Medicine · 13.05.2026 · 15 (10) · 3745
DOI: 10.3390/jcm15103745 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.05.2026. Verfasst von Tengyi Cai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Northern Clinical Diagnostics & Thrombovascular Research (NECTAR), Northern Health, Melbourne, VIC 3076, Australia. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Venous thromboembolism (VTE) remains a leading cause of global morbidity and mortality. The pathophysiological mechanisms leading to VTE are still not fully elucidated. Diagnostic biomarkers for VTE lack specificity, and biomarkers to guide the duration of anticoagulation therapy have not yet entered routine clinical practice. Proteomics has emerged as a high-throughput approach for novel biomarker discovery, offering insights into the complex biological processes across the VTE continuum. This review explores current VTE proteomic research and discusses the challenges and gaps hindering clinical translation.
Methods
We performed a narrative review based on a search of Scopus and PubMed for original human proteomic studies published between 1995 and July 2025. Results were limited to whole-blood, plasma or serum-based studies.
Results
A total of 1190 studies were retrieved, of which 27 studies were included in this review. Studies were mainly plasma-based. Studies compared VTE patients to non-VTE controls, different VTE subtypes, and various provoked VTE cohorts. Broad themes identified proteomic signatures involving dysregulated coagulation, complement activation, inflammation, and platelet activation.
Conclusions
Current proteomic evidence supports VTE as a systemic immunothrombotic disorder that shows key differences even years before developing VTE. Proteomic research in VTE holds the promise to identify biomarkers that may aid in the diagnosis and guide management of VTE. However, most proteomic findings remain exploratory to date and methodologies are varied across studies. Future studies should prioritise the workflow standardisation and validate promising biomarker panels in large-scale, prospective, longitudinal cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Northern Clinical Diagnostics & Thrombovascular Research (NECTAR), Northern Health, Melbourne, VIC 3076, Australia.
- Northern Pathology Victoria, Melbourne, VIC 3076, Australia.
- Department of Haematology, Northern Health, Melbourne, VIC 3076, Australia.
- Department of Medicine, Northern Health, University of Melbourne, Epping, VIC 3076, Australia.
- Australian Centre for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia.
- School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.
ORCID-Profile: Tengyi Cai, Julie Wang
Zitieren
APA
Cai, T., Ho, P., & Wang, J. (2026). Proteomic Biomarkers in VTE: From Discovery to Clinical Translation. Journal of Clinical Medicine, 15(10), 3745. https://doi.org/10.3390/jcm15103745
Vancouver
Cai T, Ho P, Wang J. Proteomic Biomarkers in VTE: From Discovery to Clinical Translation. Journal of Clinical Medicine. 2026;15(10):3745. doi:10.3390/jcm15103745
BibTeX
@article{Cai2026,
author = {Cai, Tengyi and Ho, Prahlad and Wang, Julie},
title = {Proteomic Biomarkers in VTE: From Discovery to Clinical Translation},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {10},
pages = {3745},
doi = {10.3390/jcm15103745}
}
EUVIMED